Dr. Wei Z. Ai

Dr. James Rubenstein is a hematologist-oncologist, or a specialist in blood disorders. He has particular expertise in treating patients with neurologic complications from cancer, including patients with non-Hodgkin's lymphoma involving the brain (called central nervous system lymphoma). He also specializes in patients with cancer that has spread to the brain from other parts of the body. In his research, Rubenstein investigates immunologic tools to improve tumor response to chemotherapy and radiation treatment, and to minimize toxicity from treatment. He is also interested in developing tumor biomarkers to diagnose brain tumors. Rubenstein earned his medical degree at Weill Cornell Medicine and completed a residency in internal medicine at Stanford Medicine. He earned a doctorate in molecular and cellular neurosciences at the Rockefeller University. He completed a fellowship in hematology and oncology at UCSF, which included training in neuro-oncology. Rubenstein has won research awards from the Leukemia & Lymphoma Society and the National Cancer Institute. He is a member of the American Society of Hematology, American Society of Clinical Oncology and American Association for Cancer Research. Dr. Rubenstein is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Primary Lymphoma of the Brain, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Vitrectomy, and Bone Marrow Aspiration. Dr. Rubenstein is board certified in American Board Of Internal Med/Medical Oncology, Medical Oncology. Dr. Rubenstein is currently accepting new patients.

Dr. Jeffrey L. Wolf is a hematologist with expertise in cancers of the bone marrow and blood, as well as in bone marrow transplantation to treat these cancers. His primary focus in both patient care and research is myeloma, the second most common blood cancer. He directs UCSF's Multiple Myeloma Program and the Stephen and Nancy Grand Multiple Myeloma Translational Initiative – a program to support the development of better treatments – at the UCSF Helen Diller Family Comprehensive Cancer Center. Wolf's current research interests are in measuring minimal residual disease in patients who have undergone successful treatment for myeloma, as the results are useful in predicting long-term survival. Wolf earned his medical degree at the University of Illinois College of Medicine at Chicago and completed a residency in medicine at the University of California, San Diego. He completed a fellowship in hematology and oncology at UCSF, followed by a bone marrow transplantation rotation at the Fred Hutchinson Cancer Research Center. In 1979, Wolf helped establish the bone marrow transplant program at the City of Hope Comprehensive Cancer Center in Duarte, California. In 1984, he helped establish the first bone marrow transplant unit based at a community hospital in the United States, at Alta Bates Summit Medical Center in Berkeley. He joined UCSF in 2007. Dr. Wolf is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Wolf is board certified in American Board Of Internal Medicine/Hematology, Hematology and American Board Of Internal Medicine, Internal Medicine. Dr. Wolf is currently accepting new patients.

Dr. Charalambos (Babis) Andreadis specializes in bone marrow transplantation for adults and in treating Hodgkin's and non-Hodgkin's lymphoma, leukemia and multiple myeloma. He cares for patients at the UCSF Helen Diller Family Comprehensive Cancer Center. His research, published widely in scientific journals, examines genetic and other factors that affect how patients respond to therapy, including degrees of drug toxicity. He also studies patient outcomes in these disorders. Andreadis earned his medical degree at Columbia University's Vagelos College of Physicians and Surgeons, and was elected to the Alpha Omega Alpha Honor Medical Society in 1998. He completed a residency at New York-Presbyterian Hospital and a fellowship in hematology and oncology at the Hospital of the University of Pennsylvania, where he joined the faculty in 2004. He also earned a master's degree in clinical epidemiology at the University of Pennsylvania, focusing on pharmacogenetics, the study of how genes impact an individual's response to medications. Dr. Andreadis is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Diffuse Large B-Cell Lymphoma (DLBCL), Large-Cell Immunoblastic Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Andreadis is board certified in American Board Of Internal Medicine/Hematology, Hematology and American Board Of Internal Med/Medical Oncology, Medical Oncology. Dr. Andreadis is currently accepting new patients.